These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7087549)

  • 21. Management of iron overload in dialysis patients.
    Winchester JF
    Semin Nephrol; 1986 Dec; 6(4 Suppl 1):22-6. PubMed ID: 3299589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship.
    Silliman CC; Peterson VM; Mellman DL; Dixon DJ; Hambidge KM; Lane PA
    J Lab Clin Med; 1993 Jul; 122(1):48-54. PubMed ID: 8320490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of nuclear magnetic resonance imaging in monitoring total body iron in hemodialysis patients with hemosiderosis treated with erythropoietin and phlebotomy.
    Chan PC; Liu P; Cronin C; Heathcote J; Uldall R
    Am J Kidney Dis; 1992 May; 19(5):484-9. PubMed ID: 1585939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis.
    Seifert A; von Herrath D; Schaefer K
    Q J Med; 1987 Dec; 65(248):1015-24. PubMed ID: 3455553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iron overload and mobilization in long-term hemodialysis patients.
    Hakim RM; Stivelman JC; Schulman G; Fosburg M; Wolfe L; Imber MJ; Lazarus JM
    Am J Kidney Dis; 1987 Oct; 10(4):293-9. PubMed ID: 3661550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iron chelating therapy in thalassemia: current problems.
    Russo G
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
    Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron removal by desferrioxamine in patients on chronic hemodialysis--kinetic study and long-term results.
    Kovarik J; Irschik H; Graf H; Woloszczuk W; Meisinger V; Linkesch W; Stummvoll HK
    Contrib Nephrol; 1985; 49():44-55. PubMed ID: 3830570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Iron-chelating treatment].
    Vullo C; Di Palma A; De Sanctis V; Borgatti L; Atti G
    Haematologica; 1989 Oct; 74(5 Suppl):241-51. PubMed ID: 2512211
    [No Abstract]   [Full Text] [Related]  

  • 30. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR; Mahony BS; Githens JH; Rhoades ED
    Am J Pediatr Hematol Oncol; 1982; 4(2):115-23. PubMed ID: 7114394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Desferrioxamine treatment for aluminium and iron overload in uraemic patients by haemodialysis or haemofiltration.
    Baldamus CA; Schmidt H; Scheuermann EH; Werner E; Kaltwasser JP; Schoeppe W
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():382-6. PubMed ID: 3991527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial.
    Kattamis A; Ladis V; Berdousi H; Kelekis NL; Alexopoulou E; Papasotiriou I; Drakaki K; Kaloumenou I; Galani A; Kattamis C
    Blood Cells Mol Dis; 2006; 36(1):21-5. PubMed ID: 16386928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects of desferrioxamine on iron elimination in children after multiple transfusions].
    Leggio ML
    Minerva Pediatr; 1966 Feb; 18(3):101-3. PubMed ID: 5930397
    [No Abstract]   [Full Text] [Related]  

  • 35. Transfusion haemosiderosis and chelation therapy.
    Ley TJ; Griffith P; Nienhuis AW
    Clin Haematol; 1982 Jun; 11(2):437-64. PubMed ID: 7042160
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical studies on iron chelation in patients with thalassemia major.
    Freedman MH; Olivieri N; Benson L; Liu P; McClelland R; St Louis P; Templeton D; Koren G
    Haematologica; 1990; 75 Suppl 5():74-83. PubMed ID: 2086384
    [No Abstract]   [Full Text] [Related]  

  • 37. [Comparison of the effectiveness of hemodialysis and hemofiltration in the removal of aluminum from the body].
    Sulková S; Laurincová Z; Pancírová J; Komonová D; Válek A
    Cas Lek Cesk; 1990 Aug; 129(32):998-1001. PubMed ID: 2208242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetics and efficacy of deferoxamine in iron-overloaded hemodialysis patients.
    Stivelman J; Schulman G; Fosburg M; Lazarus JM; Hakim RM
    Kidney Int; 1989 Dec; 36(6):1125-32. PubMed ID: 2601259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ultrafiltration studies in vitro of serum aluminum in dialysis patients after deferoxamine chelation therapy.
    Leung FY; Hodsman AB; Muirhead N; Henderson AR
    Clin Chem; 1985 Jan; 31(1):20-3. PubMed ID: 3965214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.